News

Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced that it has received conditional approval from the U.S. Food and Drug Administration (FDA) to change the study design of its ARTISAN-AF Trial, a...

BIOTRONIK, a leading manufacturer of innovative medical technology, announced today that enrollment has been completed for the highly anticipated IMPACT study. The study aims to investigate whether the use of BIOTRONIK Home Monitoring® in...

MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has acquired LAAx Inc., a privately held company that has developed a unique mechanical occlusion device called the TigerPaw® System II...

Wearable Cardioverter Defibrillators (WCD) can help decrease the number of patients that require an implantable device and also reduce unnecessary shocks DENVER – Wearable cardioverter defibrillators (WCD) can be an effective therapy option...

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced enrollment of the first patient in the EnligHTN III trial. This study will evaluate the safety and performance of the new second-generation EnligHTN™ Renal...

Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the 12-month safety and effectiveness results of the THERMOCOOL® SMARTTOUCH™ Catheter and Software Module in the treatment of...

A device commonly used to treat dangerous heart rhythms may cause more issues for patients than a simpler version of the same device. The implantable cardioverter-defibrillator (ICD) prevents sudden cardiac death by detecting irregularities...

Stryker’s Sustainability Solutions division announced today it has received two prestigious awards from the group purchasing organization Novation for supplier excellence. Novation named Stryker’s reprocessing division Purchased Services...

Boston Scientific Corporation reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN® Left Atrial Appendage (LAA) Closure device was statistically superior to warfarin for preventing...

Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the first patient has been enrolled in the reMARQable clinical study. ReMARQable will assess the safety and efficacy of the use of the...